rss
J Neurol Neurosurg Psychiatry doi:10.1136/jnnp.2008.150185

Disappearing hyperdense middle cerebral artery sign in ischemic stroke patients treated with intravenous thrombolysis - clinical course and prognostic significance

  1. Tatiana Kharitonova (tatiana.kharitonova{at}ki.se)
  1. Karolinska University, Sweden
    1. Magnus Thoren (magnus.thoren{at}karolinska.se)
    1. Karolinska University, Sweden
      1. Niaz Ahmed (niaz.ahmed{at}karolinska.se)
      1. Karolinska University, Sweden
        1. Joanna Wardlaw (joanna.wardlaw{at}ed.ac.uk)
        1. University of Edinburgh, Division of CLinical Neurosciences, United Kingdom
          1. Rudiger von Kummer (ruediger.vonkummer{at}uniklinikum-dresden.de)
          1. University of Technology, Dresden, Germany
            1. Lars Thomassen (lars.thomassen{at}helse-bergen.no)
            1. University of Bergen, Norway
              1. Nils Wahlgren (nils.wahlgren{at}karolinska.se)
              1. Karolinska University, Sweden
                • Published Online First 17 October 2008

                Abstract

                Background and purpose: Hyperdense middle cerebral artery sign (HMCAS) on computer tomography (CT) is a well-known indication of thromboembolic arterial occlusion. Its disappearance after thrombolytic therapy is poorly described. Taking the rate of HMCAS disappearance as surrogate for MCA recanalization we examined its prognostic value after intravenous thrombolysis.

                Methods: We studied 1905 stroke patients with HMCAS on admission CT scan in the Safe Implementation of Treatment in Stroke- International Stroke Thrombolysis Register (SITS-ISTR). On follow up CT scans 22-36h after thrombolysis, HMCAS disappeared in 831 cases, persisted in 788, was uncertain in 122; follow-up CT was not done in164 cases.

                Results: Patients whose HMCAS disappeared were younger (median age 67 years vs. 69 for persistent, p=0.03), with milder stroke (admission NIHSS score was 16 vs. 17, p<0.005) and were less likely to have early infarct signs on admission CT (26% vs. 33%, p<0.005). Patients with disappearing HMCAS were more likely to have early improvement in NIHSS score (median improvement 2 vs. 0 at 2h; 4 vs. 1 at 24h), be independent at three months (42% vs. 19%), with fewer deaths (15% vs. 30%), than those with persistent HMCAS. In multivariate analysis, HMCAS disappearance independently predicted functional independence and survival. Early NIHSS improvement independently predicted HMCAS disappearance.

                Conclusions: HMCAS disappeared after intravenous thrombolysis in about half of cases and these patients had twice as good outcomes compared with those with persistent HMCAS. The prognosis in patients with MCA occlusion that persists after intravenous thrombolysis is poor, which may indicate the need for alternative treatment approach to this subgroup.

                Register for free content

                The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

                Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

                BMJ Careers - Latest neurology and neurosurgery jobs